- Market Capitalization, $K 1,038,338
- Shares Outstanding, K 665,601
- Annual Sales, $ 990,270 K
- Annual Income, $ -153,040 K
- 60-Month Beta 2.20
- Price/Sales 1.07
- Price/Cash Flow N/A
- Price/Book 0.64
|Period||Period Low||Period High||Performance|
| || |
+0.05 (+3.77%)since 11/11/19
| || |
-0.63 (-29.21%)since 09/11/19
| || |
-1.81 (-54.50%)since 12/11/18
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31 Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in...
Opko Health (NASDAQ:OPK) traded in a range yesterday that spanned from a low of $1.61 to a high of $1.64. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $1.63...
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore(R) test with defined coverage criteria,...
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
OPKO Health (OPK) delivered earnings and revenue surprises of -22.22% and 1.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MIAMI (AP) _ Opko Health Inc. (OPK) on Tuesday reported a loss of $62 million in its third quarter.
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2019.
BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women's health division, GenPath, today announced the presentation of new research...
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.